ok here is why the stock has been moving:
Unigene Begins U.S. Clinical Trials with Its Nasal Osteoporosis Product
FAIRFIELD, N.J., Feb. 7 /PRNewswire/ -- Unigene Laboratories, Inc. (OTC Bulletin Board: UGNE) today announced that it has begun U.S. clinical studies for its calcitonin nasal spray product under the Investigational New Drug Application (IND) filed earlier this year. The study design is similar to that utilized in the Company's U.K. pilot study of its nasal formulation which was successfully completed last June.
Separately, Unigene announced that it has filed a patent application for its nasal formulation with the U.S. Patent and Trademark Office.
"We are pleased to have initiated the clinical phase of our development program, which we hope to complete this year," said Dr. Ronald S. Levy, Unigene's Executive Vice President. "The demand for nasal calcitonin products continues to grow and we are confident that our product will be able to achieve the high standards we have set for it."
Unigene Laboratories, Inc. is a biopharmaceutical company engaged in the research, production and delivery of valuable therapeutic peptide hormones. The Company has patented manufacturing technology for producing amidated peptides cost-effectively and in quantities sufficient to support the worldwide commercialization of peptide therapeutics for oral delivery. The Company has also patented novel oral drug delivery technology that has been shown to deliver therapeutic levels of the amidated peptide calcitonin into the bloodstream.
Except for historical information, the statements made herein are forward-looking statements involving risks and uncertainties. These risks and uncertainties, including those related to the timing or successful completion of the Company's product commercialization activities, are detailed in the Company's filings with the Securities and Exchange Commission.
SOURCE Unigene Laboratories, Inc.
CO: Unigene Laboratories, Inc.
ST: New Jersey
IN: MTC BIO
SU:
02/07/2000 08:30 EST prnewswire.com |
